MedTrace Logo

A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma

NCT01195207 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2012-11-27

No results posted yet for this study

Summary

This is a phase 1, safety study of CNTO 3157 in healthy subjects and subjects with asthma.

Conditions

Interventions

BIOLOGICAL

CNTO 3157 or placebo

0.003 mg/kg CNTO 3157 or placebo infusion

BIOLOGICAL

CNTO 3157 or placebo

0.03 mg/kg CNTO 3157 or placebo infusion

BIOLOGICAL

CNTO 3157 or placebo

10 mg/kg CNTO 3157 or placebo infusion

BIOLOGICAL

CNTO 3157 or placebo

0.01 mg/kg CNTO 3157 or placebo infusion

BIOLOGICAL

CNTO 3157 or placebo

1 mg/kg CNTO 3157 or placebo infusion

BIOLOGICAL

CNTO 3157 or placebo

3 mg/kg CNTO 3157 or placebo infusion

BIOLOGICAL

CNTO 3157 or placebo

0.3 mg/kg CNTO 3157 or placebo infusion

BIOLOGICAL

CNTO 3157 or placebo

0.1 mg/kg CNTO 3157 or placebo infusion

Sponsors & Collaborators

  • Centocor, Inc.

    lead INDUSTRY

Principal Investigators

  • Centocor, Inc. Clinical Trial · Centocor, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Completion
2012-01-31

Countries

  • Belgium
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01195207 on ClinicalTrials.gov